BioAtla Delisting Confirmed: Nasdaq Trading Suspension Set for August 31
BCAB sits 16% above its 52-week low of $2.81.
Summary
BioAtla's common stock will be suspended from Nasdaq on August 31, 2026, after the Listing Council affirmed the delisting decision. The company expects to trade on OTC Markets under BCAB, but liquidity and price may deteriorate.
Key Events · Legal and Risk Events · BCAB
-
Nasdaq Delisting Affirmed
The Nasdaq Listing Council affirmed the delisting determination on August 26, 2026, based on non-compliance with the $1.00 bid price and $2.5 million stockholders' equity requirements.
-
Trading Suspension Date Set
Trading of BCAB on Nasdaq will be suspended at the opening of business on August 31, 2026, unless the Nasdaq Board calls the matter for review.
-
OTC Markets Transition Expected
The company expects immediate eligibility for quotation on OTC Markets under symbol BCAB, which may materially reduce trading price and volume.
-
Going Concern Context
This follows the August 13, 2026 10-Q disclosure of a going concern warning with only $1.5 million in cash, insufficient for twelve months of operations.
Analysis · BCAB · Life Sciences
The Nasdaq Listing Council affirmed the delisting determination, making the suspension of trading on August 31, 2026, a near-certainty. This removes the company's primary exchange listing and forces a transition to OTC Markets, which typically reduces liquidity and institutional access. Combined with the going concern warning from the August 13 10-Q showing only $1.5 million in cash, this filing confirms the company's distressed trajectory and materially increases the risk of further value erosion for shareholders.
How filings like this one have moved
In the 30 days to Sep 14, 2026, 41.1% of the 372 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.38%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BCAB was trading at $3.25 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.2M. The 52-week trading range was $2.81 to $71.50. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.